CASI Pharmaceuticals
2
18M
2
0.06
1
- Areas of investment
Summary
CASI Pharmaceuticals appeared to be the Corporate Investor, which was created in 1991. The fund was located in North America if to be more exact in United States. The leading representative office of defined Corporate Investor is situated in the Rockville.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the CASI Pharmaceuticals, startups are often financed by Redhill Capital. The meaningful sponsors for the fund in investment in the same round are Panacea Venture, Dalton Venture.
Among the most popular portfolio startups of the fund, we may highlight Juventas. For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Among the most successful fund investment fields, there are Health Care, Biotechnology. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund.
The fund was created by John W Holaday.
The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2019.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 1
- Rounds per year
- 0.06
- Investments by industry
- Health Care (2)
- Therapeutics (1)
- Medical (1)
- Pharmaceutical (1)
- Biotechnology (1)
- Investments by region
-
- China (2)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 2
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Juventas | 09 Jul 2019 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 15M | China, Liaoning, Chaoyang City |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.